

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:08:08 ON 19 APR 2010

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FILE 'REGISTRY' ENTERED AT 10:08:19 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8
DICTIONARY FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s suramin
L1 13 SURAMIN

=> s suramin/cn
L2 1 SURAMIN/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 145-63-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,3,5-Naphthalenetrisulfonic acid,
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-
phenylene)carbonylimino]]bis- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,3,5-Naphthalenetrisulfonic acid,
8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-
phenylene)carbonylimino]]di- (8CI)
OTHER NAMES:
CN 8,8'-[Ureylenebis[m-phenylenecarbonylimino(4-methyl-m-
phenylene)carbonylimino]]di-1,3,5-naphthalenetrisulfonic acid
CN Farma
CN Farma 939
CN Fourneau
CN Metaret
CN Naganol
CN Suramin
CN Suramine
MF C51 H40 N6 O23 S6
CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, NAPRALERT, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, USPATOLD, VETU

(*File contains numerically searchable property data)


Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1810 REFERENCES IN FILE CA (1907 TO DATE)

65 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1812 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

13.59

13.81

FILE 'CAPLUS' ENTERED AT 10:08:47 ON 19 APR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 18 Apr 2010 (20100418/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:08:08 ON 19 APR 2010)

FILE 'REGISTRY' ENTERED AT 10:08:19 ON 19 APR 2010

L1 13 S SURAMIN
L2 1 S SURAMIN/CN

FILE 'CAPLUS' ENTERED AT 10:08:47 ON 19 APR 2010

=> s l2

L3 1812 L2

=> s l2 and (composition or kit)

1812 L2
781624 COMPOSITION
362441 COMPOSITIONS
1135570 COMPOSITION
(COMPOSITION OR COMPOSITIONS)
47805 KIT
44996 KITS
78355 KIT

(KIT OR KITS)
L4 128 L2 AND (COMPOSITION OR KIT)

=> s l4 and ad<20010924

4162029 AD<20010924
(AD<20010924)

L5 24 L4 AND AD<20010924

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 24 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 1-24 ibib abs

L6 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1312067 CAPLUS
DOCUMENT NUMBER: 146:41053
TITLE: Optical fluorescent imaging
INVENTOR(S): Kovar, Joy; Chen, Jiyan; Draney, Daniel R.; Olive, D.
Michael; Volcheck, William M.; Xu, Xinshe; Lugade,
Ananda G.; Narayanan, Narasimhachari
PATENT ASSIGNEE(S): Li-Cor, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S.
Ser. No. 267,643.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060280688	A1	20061214	US 2006-419457	20060519
US 7597878	B2	20091006		
WO 2002024815	A1	20020328	WO 2001-US29385	20010918 <--
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 20040014981	A1	20040122	US 2003-354812	20030128
US 6995274	B2	20060207		
US 20060063247	A1	20060323	US 2005-267643	20051104
US 7504089	B2	20090317		
CA 2651937	A1	20071129	CA 2007-2651937	20070509
WO 2007136996	A1	20071129	WO 2007-US68564	20070509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2035505	A1	20090318	EP 2007-762058	20070509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20100080758	A1	20100401	US 2009-572674	20091002
PRIORITY APPLN. INFO.:				
			US 2000-233511P	P 20000919
			WO 2001-US29385	A1 20010918
			US 2003-354812	A3 20030128
			US 2005-267643	A2 20051104
			US 2006-419457	A 20060519
			WO 2007-US68564	W 20070509

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:41053

AB Compds. and methods are disclosed that are useful for noninvasive imaging in the near-IR (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a

tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:471831 CAPLUS
DOCUMENT NUMBER: 143:1254
TITLE: Combinations and methods for treating neoplasms
INVENTOR(S): Yu, Baofa
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S.
Ser. No. 765,060.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050118187	A1	20050602	US 2004-973798	20041025
US 20020044919	A1	20020418	US 2001-765060	20010117 <--
US 6811788	B2	20041102		
PRIORITY APPLN. INFO.:			US 2000-177024P	P 20000119
			US 2001-765060	A2 20010117

AB Methods for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments, are provided. Also provided are combinations, and kits containing the combinations for effecting the therapy.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)

L6 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:133580 CAPLUS
DOCUMENT NUMBER: 138:183487
TITLE: ADP natural ligand binding to human orphan G protein coupled receptor GPR86 and its use in screening assays and diagnosis and treatment of GPR86-associated diseases
INVENTOR(S): Communi, Didier; Suarez, Nathalie; Detheux, Michel; Brezillon, Stephane; Lannoy, Vincent; Parmentier, Marc; Boeynaems, Jean-Marie
PATENT ASSIGNEE(S): Euroscreen S.A., Belg.
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014731	A2	20030220	WO 2002-EP8761	20020806
WO 2003014731	A3	20040219		
W: CA, JP				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				

US 20030050235	A1	20030313	US 2001-924125	20010807 <--
US 6946244	B2	20050920		
CA 2453486	A1	20030220	CA 2002-2453486	20020806
EP 1421377	A2	20040526	EP 2002-748870	20020806
EP 1421377	B1	20060426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
JP 2005500053	T	20050106	JP 2003-519412	20020806
JP 4372545	B2	20091125		
AT 324585	T	20060515	AT 2002-748870	20020806
ES 2262819	T3	20061201	ES 2002-748870	20020806
US 20040005629	A1	20040108	US 2002-308968	20021203
US 20060078918	A1	20060413	US 2005-216987	20050831
US 7422846	B2	20080909		

PRIORITY APPLN. INFO.:

US 2001-924125	A	20010807
WO 2002-EP8761	W	20020806
US 2002-308968	A3	20021203

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is related to the human G protein coupled receptor GPR86 (purinoceptor P2Y13) and any homologous sequence thereto. Also provided are recombinant cells comprising the nucleotide sequence encoding the receptor, and the identification of the natural ligand, ADP, and equivalent mols. to be used in screening assays for identification of agonists, inverse agonists or antagonist compds. useful for the development of new drugs, and the improvement of various disease diagnostics. The present invention further relates to the identification of ATP, 2MeSATP, 2MeSADP, ADP β S, Ap3A, RB-2, Suramine and PPADS as modulators of GPR86 activity.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:465785 CAPLUS
DOCUMENT NUMBER: 137:37413
TITLE: Cosmetic composition comprising heparanase
INVENTOR(S): Bernard, Dominique; Mehul, Bruno; Simonetti, Lucie
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002047654	A2	20020620	WO 2001-FR3936	20011211
WO 2002047654	A3	20020801		
W: CA, JP, OM, PH, TN, US, ZM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2818131	A1	20020621	FR 2000-16320	20001214 <--
FR 2818131	B1	20050211		

PRIORITY APPLN. INFO.:

FR 2000-16320	A	20001214
---------------	---	----------

AB The invention concerns a cosmetic composition comprising at least heparanase. The invention also concerns the uses of heparanase in a composition or for preparing a composition for the skin and/or hair, and a cosmetic treatment method for the skin and/or hair. The presence of heparanase in the human epidermal cells is demonstrated. A cleansing gel contained butylene

glycol 7.0, sodium lauroyl sarcosinate 4.0, heparanase 0.1,
triethanolamine 0.8, carbomer 0.5, preservatives q.s., and water q.s.
100.0%.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:221202 CAPLUS

DOCUMENT NUMBER: 136:257216

TITLE: Compositions and methods for treating
infections using cationic peptides alone or in
combination with antibiotics

INVENTOR(S): Krieger, Timothy J.; Taylor, Robert; Erfle, Douglas;
Fraser, Janet R.; West, Michael H. P.; McNichol,
Patricia J.

PATENT ASSIGNEE(S): Micrologix Biotech, Inc, Can.

SOURCE: U.S. Pat. Appl. Publ., 111 pp., Cont.-in-part of U. S.
6,180,604.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20020035061	A1	20020321	US 1998-30619	19980225 <--
US 6503881	B2	20030107		
US 6180604	B1	20010130	US 1997-915314	19970820 <--
EP 1174439	A2	20020123	EP 2001-119148	19970821 <--
EP 1174439	A3	20030326		
EP 1174439	B1	20081008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CA 2282807	A1	19980917	CA 1998-2282807	19980310 <--
AU 9866047	A	19980929	AU 1998-66047	19980310 <--
EP 966481	A2	19991229	EP 1998-907779	19980310 <--
EP 966481	B1	20060719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002544759	T	20021224	JP 1998-538997	19980310 <--
AT 333464	T	20060815	AT 1998-907779	19980310 <--
ES 2264198	T3	20061216	ES 1998-907779	19980310 <--
HK 1025103	A1	20060929	HK 2000-103705	20000620 <--
US 6538106	B1	20030325	US 2000-667486	20000922 <--
US 20030232750	A1	20031218	US 2002-277233	20021018
US 7309759	B2	20071218		
US 20040009910	A1	20040115	US 2003-351985	20030124
US 7390787	B2	20080624		
JP 2005225857	A	20050825	JP 2004-242925	20040823
JP 4073900	B2	20080409		
US 20080242614	A1	20081002	US 2008-58500	20080328
PRIORITY APPLN. INFO.:			US 1996-24754P	P 19960821
			US 1997-34949P	P 19970113
			US 1997-40649P	P 19970310
			US 1997-915314	A2 19970820
			US 1997-60099P	P 19970926
			EP 1997-941352	A3 19970821
			JP 1998-510994	A3 19970821
			US 1998-30619	A 19980225

WO 1998-CA190 W 19980310
 US 2000-667486 A1 20000922
 US 2003-351985 A1 20030124

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:257216

AB Compns. and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogs containing at least two basic amino acids are prepared. The analogs are administered as modified peptides, preferably containing photo-oxidized solubilizer.

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

L6 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:960660 CAPLUS

DOCUMENT NUMBER: 138:19488

TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases

INVENTOR(S): Hunter, William L.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002 37,919.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495579	B1	20021217	US 1998-88546	19980601 <--
US 20020037919	A1	20020328	US 1997-980549	19971201 <--
US 6515016	B2	20030204		
CA 2607067	A1	19980611	CA 1997-2607067	19971202 <--
EP 1070502	A2	20010124	EP 2000-123557	19971202 <--
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202 <--
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202 <--
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A	20020814	JP 2001-401899	19971202 <--
EP 1582210	A2	20051005	EP 2005-11601	19971202 <--
EP 1582210	A3	20051012		
EP 1582210	B1	20100210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1679937	A	20051012	CN 2005-10054770	19971202 <--
CN 101011576	A	20070808	CN 2006-10099927	19971202 <--
CN 101195028	A	20080611	CN 2006-10099895	19971202 <--
WO 9962510	A2	19991209	WO 1999-CA464	19990601 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				

TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20020013298	A1	20020131	US 1999-368463	19990804 <--
US 20020183380	A1	20021205	US 2002-67467	20020205
US 6689803	B2	20040210		
US 20030157187	A1	20030821	US 2002-172737	20020613
US 20050249770	A1	20051110	US 2005-102587	20050408
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
US 20080113035	A1	20080515	US 2007-891651	20070810
US 20080153900	A1	20080626	US 2007-891661	20070810
JP 2009161555	A	20090723	JP 2009-57154	20090310
PRIORITY APPLN. INFO.:			US 1996-32215P	P 19961202
			US 1997-63087P	P 19971024
			US 1997-980549	A2 19971201
			CA 1997-2273240	A3 19971202
			CN 1997-181581	A3 19971202
			CN 2005-10054770	A3 19971202
			EP 1997-945697	A3 19971202
			EP 2000-123537	A3 19971202
			JP 1998-524997	A3 19971202
			JP 2001-401899	A3 19971202
			US 1998-88546	A 19980601
			US 1999-368463	B1 19990804
			US 1999-368871	A1 19990804
			US 2002-172737	B1 20020613
			AU 2004-200715	A3 20040220
			US 2005-102587	B1 20050408

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising delivering to the site of inflammation an anti-microtubule agent (e.g. paclitaxel), or analog or derivative thereof.

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:545502 CAPLUS

DOCUMENT NUMBER: 135:117219

TITLE: Hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms

INVENTOR(S): Yu, Baofa

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001052868	A1	20010726	WO 2001-US1737	20010118 <--
WO 2001052868	A9	20030116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,			

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2397598 A1 20010726 CA 2001-2397598 20010118 <--
JP 2004505009 T 20040219 JP 2001-552915 20010118 <--
CN 1273146 C 20060906 CN 2001-806830 20010118 <--
AU 2001230977 B2 20061012 AU 2001-230977 20010118 <--
PRIORITY APPLN. INFO.: US 2000-177024P P 20000119
WO 2001-US1737 W 20010118

AB Methods are provided for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments. Also provided are combinations, and kits containing the combinations for effecting the therapy.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:163436 CAPLUS

DOCUMENT NUMBER: 134:219376

TITLE: Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms

INVENTOR(S): Marks, Rory M.; Chen, Yaping; Maguire, Terence; Linhardt, Robert J.

PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA

SOURCE: U.S., 29 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6197568	B1	20010306	US 1998-123770	19980728 <--
PRIORITY APPLN. INFO.:			US 1997-53828P	P 19970729

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods and compns. for the isolation, diagnosis and treatment of microorganisms such as flaviviruses and other hemorrhagic fever viruses are based on the sulfated polyanion-dependent interaction of flaviviruses and hemorrhagic fever viruses, in particular dengue virus, with target cells. The cellular receptors targeted by these viruses have been identified as sulfated polyanionic glycoproteins, that include highly sulfated heparan sulfate glycosaminoglycans for some target cell types, and as a sulfated mucin on vascular endothelium. Compds. such as heparin, highly sulfated heparan sulfate, and synthetic polyanions such as Suramin, inhibit the interaction between the microorganisms and target cells, thereby disrupting the infective process.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:880923 CAPLUS

DOCUMENT NUMBER: 134:37055

TITLE: Methods and compositions using FGF inhibitors and agonists for modulating cell proliferation and cell death

INVENTOR(S): Au, Jessie L. S.; Wientjes, M. Guillaume

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074634	A2	20001214	WO 2000-US40103	20000605 <--
WO 2000074634	A3	20010823		
WO 2000074634	A9	20020926		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377385	A1	20001214	CA 2000-2377385	20000605 <--
EP 1206234	A2	20020522	EP 2000-943429	20000605 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503313	T	20030128	JP 2001-501171	20000605 <--
US 6599912	B1	20030729	US 2000-587559	20000605 <--
AU 780454	B2	20050324	AU 2000-57903	20000605 <--
IL 146872	A	20061031	IL 2000-146872	20000605 <--
KR 903243	B1	20090617	KR 2001-715591	20011203
US 20040010001	A1	20040115	US 2003-464018	20030618
US 7625860	B2	20091201		

PRIORITY APPLN. INFO.:

US 1999-137345P	P	19990603
US 1999-165983P	P	19991117
US 1999-172031P	P	19991223
US 2000-187445P	P	20000307
US 2000-587559	A3	20000605
WO 2000-US40103	W	20000605

AB Methods and compns. for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compns. for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compns. include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promote apoptosis and/or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes administering to the subject an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing

the damage to the dividing cell from said cytotoxic agent. FGF gene expression-based methods for diagnosis of proliferative disorders are also disclosed.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:783929 CAPLUS

DOCUMENT NUMBER: 132:18780

TITLE: Compositions comprising antimicrotubule agents for treating or preventing inflammatory diseases

INVENTOR(S): Hunter, William L.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 340 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962510	A2	19991209	WO 1999-CA464	19990601 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6495579	B1	20021217	US 1998-88546	19980601 <--
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
PRIORITY APPLN. INFO.:			US 1998-88546	A 19980601
			US 1996-32215P	P 19961202
			US 1997-63087P	P 19971024
			US 1997-980549	A2 19971201
			AU 2004-200715	A3 20040220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising the step of delivering to the site of inflammation an antimicrotubule agent, or analog or derivative thereof.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:659226 CAPLUS

DOCUMENT NUMBER: 131:281600

TITLE: Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin

INVENTOR(S): Fisher, Gary J.; Voorhees, John J.

PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951220	A1	19991014	WO 1999-US7267	19990402 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 234455	B	20050621	TW 1999-88104581	19990323 <--
CA 2326507	A1	19991014	CA 1999-2326507	19990402 <--
AU 9936374	A	19991025	AU 1999-36374	19990402 <--
AU 740569	B2	20011108		
BR 9909899	A	20001226	BR 1999-9899	19990402 <--
EP 1067920	A1	20010117	EP 1999-918456	19990402 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002510621	T	20020409	JP 2000-541991	19990402 <--
US 6683069	B1	20040127	US 1999-285860	19990402 <--
MX 2000009651	A	20010622	MX 2000-9651	20001002 <--
IN 2000CN00570	A	20050304	IN 2000-CN570	20001025 <--
US 20040208836	A1	20041021	US 2003-691076	20031022
US 7141238	B2	20061128		

PRIORITY APPLN. INFO.:
US 1998-80437P P 19980402
US 1999-285860 A3 19990402
WO 1999-US7267 W 19990402

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Exposure of human skin to UV radiation from the sun not only induces the production of enzymes (matrix metalloproteinases) that degrade collagen, but also inhibits the synthesis of new collagen by inhibiting the synthesis of procollagen. This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to its exposure to UV radiation. It was shown that retinoids such as retinoic acid protect human skin in vivo against the UV-induced inhibition of collagen synthesis.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:311294 CAPLUS

DOCUMENT NUMBER: 130:320846

TITLE: Cardiac myocyte test cells for screening for effectors of P2 purinoceptors that improve cardiac contractility
Li, Liang, Bruce T.

INVENTOR(S): The Trustees of the University of Pennsylvania, USA

PATENT ASSIGNEE(S): PCT Int. Appl., 77 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9923214 A1 19990514 WO 1998-US23170 19981030 <--
W: AU, CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
AU 9913709 A 19990524 AU 1999-13709 19981030 <--
PRIORITY APPLN. INFO.: US 1997-64329P P 19971030
WO 1998-US23170 W 19981030

AB Cardiac myocytes, either native or transgenic, bearing P2 purinoceptors, such as the P2X4 or P2X6 isoforms, are described for use in screening for effectors of cardiac contractility. A method of augmenting cardiac contractility and a method of treating heart failure are included in the invention, as is a kit comprising one or more recombinant myocytes and an instructional material. The establishment of cultured myocytes that are responsive to purinoceptor agonists is described. Transgenic myocytes expressing a cloned gene for the P2X4 isoform using the com. vector pcDNA3 showed a stronger response to 2-methylthio-ATP than did control cells.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:682102 CAPLUS
DOCUMENT NUMBER: 129:285998
ORIGINAL REFERENCE NO.: 129:58149a,58152a
TITLE: Therapeutic cytostatic and/or cytoskeletal inhibitor
for vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L.; Klein, Richard A.; Reno, John M.
PATENT ASSIGNEE(S): Neorx Corp., USA
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843618	A2	19981008	WO 1998-US6322	19980331 <--
WO 9843618	A3	19981105		
W: BR, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1826280	A2	20070829	EP 2007-7189	19920925 <--
EP 1826280	A3	20071205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
US 5981568	A	19991109	US 1997-829685	19970331 <--
CA 2285389	A1	19981008	CA 1998-2285389	19980331 <--
CA 2285389	C	20081230		
EP 975340	A2	20000202	EP 1998-914366	19980331 <--
EP 975340	B1	20041006		
EP 975340	B2	20091028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808109	A	20000308	BR 1998-8109	19980331 <--
JP 2001521503	T	20011106	JP 1998-541922	19980331 <--
AT 278397	T	20041015	AT 1998-914366	19980331 <--
PRIORITY APPLN. INFO.:			US 1997-829685	A 19970331
			US 1997-829991	A 19970331
			EP 1994-911762	A3 19920925
			EP 2003-15404	A3 19920925
			US 1993-62451	B1 19930513

US 1995-389712	A2 19950215
US 1995-450793	A2 19950525
WO 1996-US2125	A2 19960215
WO 1998-US6322	W 19980331

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biol. stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compns. and kits comprising the therapeutic agents of the invention.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:147346 CAPLUS

DOCUMENT NUMBER: 128:213381

ORIGINAL REFERENCE NO.: 128:42137a, 42140a

TITLE: Compositions and methods for treating infections using analogs of indolicidin

INVENTOR(S): Fraser, Janet R.; West, Michael H. P.; Krieger, Timothy J.; Taylor, Robert; Erfle, Douglas

PATENT ASSIGNEE(S): Micrologix Biotech, Inc., Can.

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807745	A2	19980226	WO 1997-US14779	19970821 <--
WO 9807745	A3	19980709		
W:	AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AZ			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2263799	A1	19980226	CA 1997-2263799	19970821 <--
AU 9743279	A	19980306	AU 1997-43279	19970821 <--
EP 925308	A2	19990630	EP 1997-941352	19970821 <--
EP 925308	B1	20020605		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001500477	T	20010116	JP 1998-510994	19970821 <--
EP 1174439	A2	20020123	EP 2001-119148	19970821 <--
EP 1174439	A3	20030326		
EP 1174439	B1	20081008		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AT 218579	T	20020615	AT 1997-941352	19970821 <--
ES 2178000	T3	20021216	ES 1997-941352	19970821 <--
AT 410441	T	20081015	AT 2001-119148	19970821 <--
ES 2315252	T3	20090401	ES 2001-119148	19970821 <--

HK 1021824	A1	20030221	HK 1999-106212	19991230 <--
HK 1043475	A1	20090703	HK 2002-105059	20020708
US 20040009910	A1	20040115	US 2003-351985	20030124
US 7390787	B2	20080624		
JP 2005225857	A	20050825	JP 2004-242925	20040823
JP 4073900	B2	20080409		
US 20080242614	A1	20081002	US 2008-58500	20080328

PRIORITY APPLN. INFO.:

US 1996-24754P	P	19960821
US 1997-34949P	P	19970113
US 1997-915314	A1	19970820
EP 1997-941352	A3	19970821
JP 1998-510994	A3	19970821
WO 1997-US14779	W	19970821
US 2000-667486	A1	20000922
US 2003-351985	A1	20030124

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:213381

AB Compsn. and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogs containing at least two basic amino acids are prepared. The analogs are administered as modified peptides, preferably containing photo-oxidized solubilizer.

OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:87615 CAPLUS

DOCUMENT NUMBER: 128:139449

ORIGINAL REFERENCE NO.: 128:27403a,27404a

TITLE: Pharmaceutical compositions containing P2Y purinergic receptor antagonists

INVENTOR(S): Brown, Frank; Mitchell, Davina Elizabeth; Rahim, Ariyan Tufiq; Stewart, Brian Robert

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9803178	A2	19980129	WO 1997-EP3844	19970715 <--
WO 9803178	A3	19980319		

W: JP, US, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: GB 1996-15202 A 19960719

AB The use of a P2Y receptor antagonist, in particular, a P2Y1 receptor antagonist, in the manufacture of a medicament for use in the treatment of CNS neurodegenerative disorders where an inflammatory component has been suggested (such as Alzheimer's disease) or peripheral demyelinating diseases, such as Guillain Barre syndrome and central demyelinating diseases, such as multiple sclerosis. The P2Y1 receptor antagonists include suramin, Cibacron Blue, PPADS, and DIDS.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:58964 CAPLUS
DOCUMENT NUMBER: 128:119711
ORIGINAL REFERENCE NO.: 128:23367a,23370a
TITLE: Methods and compositions for the treatment
and repair of defects or lesions in cartilage or bone
using functional barrier
INVENTOR(S): Hunziker, Ernst B.
PATENT ASSIGNEE(S): Shaw, Robert Francis, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9800183	A2	19980108	WO 1997-US11208	19970624 <--
WO 9800183	A3	19980212		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,				
EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO,				
RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
GN, ML, MR, NE, SN, TD, TG				
US 5853746	A	19981229	US 1996-672618	19960628 <--
CA 2258601	A1	19980108	CA 1997-2258601	19970624 <--
CA 2258601	C	20070410		
AU 9735815	A	19980121	AU 1997-35815	19970624 <--
AU 731172	B2	20010322		
EP 912204	A2	19990506	EP 1997-932329	19970624 <--
EP 912204	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI				
BR 9710088	A	19990810	BR 1997-10088	19970624 <--
CN 1226839	A	19990825	CN 1997-196887	19970624 <--
CN 1321681	C	20070620		
NZ 333452	A	20000428	NZ 1997-333452	19970624 <--
JP 2000513721	T	20001017	JP 1998-504318	19970624 <--
IL 127550	A	20040601	IL 1997-127550	19970624 <--
AT 327781	T	20060615	AT 1997-932329	19970624 <--
ES 2267145	T3	20070301	ES 1997-932329	19970624 <--
TW 505518	B	20021011	TW 1997-86108885	19970625 <--
ZA 9705711	A	19980126	ZA 1997-5711	19970626 <--
NO 9806083	A	19990301	NO 1998-6083	19981223 <--
NO 320089	B1	20051024		
KR 2000022182	A	20000425	KR 1998-710600	19981224 <--
HK 1017276	A1	20070119	HK 1999-102149	19990513 <--
PRIORITY APPLN. INFO.:			US 1996-672618	A 19960628
			US 1991-648274	A3 19910131
			US 1992-979904	A1 19921123
			US 1994-333156	B1 19941101
			US 1995-524034	B2 19950906
			WO 1997-US11208	W 19970624

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods and compns. are provided for the treatment and repair of defects
in the cartilage or bone of humans and other animals as in full-thickness
defects in joints. To induce cartilage formation, a defect in cartilage
is filled with a matrix having pores sufficiently large to allow cartilage
repair cells to populate the matrix. The matrix contains an

anti-angiogenic agent that serves as a functional barrier to prevent vascularization and bone growth into the cartilage area. The matrix for filling the defect in cartilage may also contain a proliferation agent and a chemotactic agent, and a transforming factor in an appropriate delivery system. A functional barrier between the bone and cartilage areas of a full-thickness defect may also be created by heat-treating the areas of bleeding to form a transient tissue barrier which prevents blood vessels and associated cells from penetrating from the bone area into the cartilage area. If desired, the bone portion of the full-thickness defect may be filled with a matrix having pores large enough to allow cells to populate the matrix and to form blood vessels. The matrix filling the bone defect may contain an angiogenic factor and an osteogenic factor in an appropriate delivery system. Methods and compns. are also provided for assisted bone and connective tissue regeneration for dental and other applications. Created defects in the knee joints of rabbits were treated with chondroitinase ABC, then filled with a fibrin matrix, formed by mixing thrombin solution with fibrinogen solution After 1 mo, the joints showed

affinity of the fibrin matrixes in defect areas.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:803799 CAPLUS

DOCUMENT NUMBER: 128:66489

ORIGINAL REFERENCE NO.: 128:12915a,12918a

TITLE: Compositions and methods for treating or preventing diseases of body passageways

INVENTOR(S): Hunter, William L.; Machan, Lindsay S.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.; University of British Columbia; Hunter, William L.; Machan, Lindsay S.

SOURCE: PCT Int. Appl., 207 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9745105	A1	19971204	WO 1997-CA345	19970526 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
NZ 517544	A	20031031	NZ 1997-517544	19970524 <--
NZ 527950	A	20050429	NZ 1997-527950	19970524 <--
NZ 538543	A	20061027	NZ 1997-538543	19970524 <--
CA 2255891	A1	19971204	CA 1997-2255891	19970526 <--
CA 2255891	C	20071204		
CA 2592932	A1	19971204	CA 1997-2592932	19970526 <--
AU 9727604	A	19980105	AU 1997-27604	19970526 <--
AU 737078	B2	20010809		
EP 914102	A1	19990512	EP 1997-921563	19970526 <--
EP 914102	B1	20050824		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

CN 1219872	A	19990616	CN 1997-194908	19970526 <--
BR 9710682	A	19990817	BR 1997-10682	19970526 <--
JP 2000511161	T	20000829	JP 1997-541313	19970526 <--
NZ 505584	A	20020426	NZ 1997-505584	19970526 <--
AT 302599	T	20050915	AT 1997-921563	19970526 <--
EP 1616563	A2	20060118	EP 2005-18291	19970526 <--
EP 1616563	A3	20060125		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, AL

ES 2248847	T3	20060316	ES 1997-921563	19970526 <--
NO 9805463	A	19990121	NO 1998-5463	19981123 <--
KR 2000015944	A	20000315	KR 1998-709500	19981124 <--
HK 1020007	A1	20060113	HK 1999-105188	19991111 <--
AU 775787	B2	20040812	AU 2001-51987	20010618 <--
US 20020052404	A1	20020502	US 2001-933652	20010820 <--
US 6759431	B2	20040706		
US 20040224023	A1	20041111	US 2003-671327	20030925
JP 2004285074	A	20041014	JP 2004-145728	20040514
AU 2004202838	A1	20040722	AU 2004-202838	20040625
AU 2004202838	B2	20080529		
US 20050192235	A1	20050901	US 2004-969759	20041019
US 20050107291	A1	20050519	US 2004-970705	20041020
US 20050096388	A1	20050505	US 2004-970638	20041021
US 20050101635	A1	20050512	US 2004-972307	20041021
US 20050129736	A1	20050616	US 2004-972245	20041022
US 20050137148	A1	20050623	US 2004-972306	20041022
NO 2004005602	A	19990121	NO 2004-5602	20041222
US 20060121088	A1	20060608	US 2005-294655	20051205

PRIORITY APPLN. INFO.:

US 1996-653207	A	19960524
NZ 1997-332638	A3	19970524
AU 1997-27604	A3	19970526
CA 1997-2255891	A3	19970526
EP 1997-921563	A3	19970526
JP 1997-541313	A3	19970526
WO 1997-CA345	W	19970526
AU 2001-51987	A3	20010618
US 2001-933652	A1	20010820
US 2003-671327	A1	20030925

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics. Pastes and nanosprays containing polycaprolactone were prepared

OS.CITING REF COUNT: 79 THERE ARE 79 CAPLUS RECORDS THAT CITE THIS RECORD (79 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:374878 CAPLUS

DOCUMENT NUMBER: 126:338852

ORIGINAL REFERENCE NO.: 126:65747a,65750a

TITLE: A pharmaceutical composition using a cytokine-suppressing anti-inflammatory agent and an immunosuppressant for the treatment of autoimmune diseases

INVENTOR(S): Guglielmotti, Angelo; Dionisio, Paolo

PATENT ASSIGNEE(S): Angelini Ricerche S.P.A. Societa' Consortile, Italy;

SOURCE: Guglielmotti, Angelo; Dionisio, Paolo
PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716185	A2	19970509	WO 1996-EP4672	19961026 <--
WO 9716185	A3	19970703		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2236256	A1	19970509	CA 1996-2236256	19961026 <--
CA 2236256	C	20050222		
AU 9674938	A	19970522	AU 1996-74938	19961026 <--
AU 721841	B2	20000713		
EP 858337	A2	19980819	EP 1996-937258	19961026 <--
EP 858337	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1207042	A	19990203	CN 1996-199472	19961026 <--
CN 1229113	C	20051130		
BR 9611320	A	19990302	BR 1996-11320	19961026 <--
HU 9901303	A2	19990928	HU 1999-1303	19961026 <--
HU 9901303	A3	20010428		
JP 11515020	T	19991221	JP 1997-517053	19961026 <--
JP 4007615	B2	20071114		
NZ 321580	A	20000228	NZ 1996-321580	19961026 <--
IL 124291	A	20010614	IL 1996-124291	19961026 <--
CZ 292258	B6	20030813	CZ 1998-1326	19961026 <--
PL 186377	B1	20031231	PL 1996-326371	19961026 <--
SK 284069	B6	20040908	SK 1998-579	19961026 <--
AT 326965	T	20060615	AT 1996-937258	19961026 <--
PT 858337	E	20060929	PT 1996-937258	19961026 <--
ES 2264144	T3	20061216	ES 1996-937258	19961026 <--
ZA 9609060	A	19970529	ZA 1996-9060	19961028 <--
NO 9801951	A	19980629	NO 1998-1951	19980429 <--
NO 324130	B1	20070903		
US 6020356	A	20000201	US 1998-68011	19980903 <--
HK 1018219	A1	20060519	HK 1999-103337	19990803 <--

PRIORITY APPLN. INFO.:

IT 1995-MI2242 A 19951031
WO 1996-EP4672 W 19961026

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A pharmaceutical composition is disclosed which comprises an anti-inflammatory drug capable of suppressing the production of cytokines (CSAID), an immunosuppressant, and a pharmaceutically acceptable excipient. Use of CSAIDS allow reduction of the immunosuppressant dose in the prolonged treatment of autoimmune disease without reducing therapeutic efficacy, thus improving tolerability. Results of a clin. study shows that bindarit significantly reduced the the severity of nephritis complications in patients suffering from systemic lupus erythematosus treated with corticosteroids.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:394840 CAPLUS

DOCUMENT NUMBER: 127:76021

ORIGINAL REFERENCE NO.: 127:14365a,14368a

TITLE: Compositions and methods using phenylacetic acid derivatives for therapy and prevention of pathologies, including cancer, AIDS and anemia

INVENTOR(S): Samid, Dvorit

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 779,774.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5635532	A	19970603	US 1993-135661	19931012 <--
US 6037376	A	20000314	US 1991-779744	19911021 <--
EP 1108427	A2	20010620	EP 2000-126980	19921013 <--
EP 1108427	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 1108428	A2	20010620	EP 2000-126981	19921013 <--
EP 1108428	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
ES 2171400	T3	20020916	ES 1992-922550	19921013 <--
EP 1484058	A2	20041208	EP 2004-15994	19921013 <--
EP 1484058	A3	20050427		
EP 1484058	B1	20081231		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 1484059	A2	20041208	EP 2004-15995	19921013 <--
EP 1484059	A3	20050420		
EP 1484059	B1	20080903		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
AT 406883	T	20080915	AT 2004-15995	19921013 <--
AT 418975	T	20090115	AT 2004-15994	19921013 <--
ES 2312884	T3	20090301	ES 2004-15995	19921013 <--
ZA 9208140	A	19940421	ZA 1992-8140	19921021 <--
CA 2108963	A1	19950422	CA 1993-2108963	19931021 <--
CA 2108963	C	19990316		
US 5605930	A	19970225	US 1994-207521	19940307 <--
IL 111251	A	20040620	IL 1994-111251	19941011 <--
CA 2173976	A1	19950420	CA 1994-2173976	19941012 <--
CA 2173976	C	20080219		
WO 9510271	A2	19950420	WO 1994-US11492	19941012 <--
WO 9510271	A3	19950622		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 702051	B2	19950504	AU 1994-79737	19941012 <--
AU 9479737	A	19950504		
ZA 9407964	A	19960306	ZA 1994-7964	19941012 <--
EP 725635	A1	19960814	EP 1994-930694	19941012 <--
EP 725635	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09506079	T	19970617	JP 1995-511977	19941012 <--

JP 3628694	B2	20050316		
NZ 275673	A	20000929	NZ 1994-275673	19941012 <--
JP 2001253821	A	20010918	JP 2001-69516	19941012 <--
JP 2003119130	A	20030423	JP 2002-302292	19941012 <--
AT 285760	T	20050115	AT 1994-930694	19941012 <--
EP 1523982	A2	20050420	EP 2004-30912	19941012 <--
EP 1523982	A3	20050427		
EP 1523982	B1	20080312		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT

PT 725635	E	20050531	PT 1994-930694	19941012 <--
ES 2233931	T3	20050616	ES 1994-930694	19941012 <--
AT 388699	T	20080315	AT 2004-30912	19941012 <--
PT 1523982	E	20080625	PT 2004-30912	19941012 <--
ES 2303624	T3	20080816	ES 2004-30912	19941012 <--
US 5635533	A	19970603	US 1995-470229	19950606 <--
US 5654333	A	19970805	US 1995-465941	19950606 <--
US 5661179	A	19970826	US 1995-469466	19950606 <--
US 5708025	A	19980113	US 1995-465835	19950606 <--
US 5710178	A	19980120	US 1995-469691	19950606 <--
US 5712307	A	19980127	US 1995-465924	19950606 <--
US 5843994	A	19981201	US 1995-478264	19950607 <--
US 5877213	A	19990302	US 1995-484817	19950607 <--
US 5883124	A	19990316	US 1995-484615	19950607 <--
US 5852056	A	19981222	US 1996-633833	19960410 <--
HK 1067551	A1	20081031	HK 2005-100026	20050104
JP 2005139208	A	20050602	JP 2005-54743	20050228
JP 2005139209	A	20050602	JP 2005-54744	20050228
HK 1077204	A1	20090206	HK 2005-109253	20051020

PRIORITY APPLN. INFO.:

US 1991-779744	A2	19911021
EP 1992-922550	A3	19921013
US 1993-135661	A2	19931012
US 1994-207521	A	19940307
EP 1994-930694	A3	19941012
JP 1995-511977	A3	19941012
JP 2001-69516	A3	19941012
WO 1994-US11492	W	19941012
EP 2000-126980	A3	20001208
EP 2000-126981	A3	20001208

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 127:76021

AB Compns. and methods are disclosed for treating anemia, cancer, AIDS, or severe β -chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivs. thereof or derivs. thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacol.-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. Compds. of the invention include R0C(R1)(R2)[C(R3)(R4)]nC(O)OH [R0 = (substituted) Ph, (substituted) naphthyl, (substituted) phenoxy, where the substitution is 1-4 halo moieties, OH, lower straight-chain or branched alkyl; R1, R2 = H, OH, lower alkoxy, halo, lower straight-chain or branched alkyl; R3, R4 = H, lower alkoxy, halo, lower straight-chain or branched alkyl; n = 0-2] and pharmaceutically acceptable salts and mixts. thereof.

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:196180 CAPLUS

DOCUMENT NUMBER: 126:207539

ORIGINAL REFERENCE NO.: 126:40001a
 TITLE: Compositions and methods using phenylacetate compounds, alone or in combination with other therapeutic agents, for treating and preventing anemia, cancer, and other pathologies and modulating lipid metabolism
 INVENTOR(S): Samid, Dvorit
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
 SOURCE: U.S., 111 pp., Cont.-in-part of U.S. Ser. No. 135,661.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5605930	A	19970225	US 1994-207521	19940307 <--
US 6037376	A	20000314	US 1991-779744	19911021 <--
EP 1108427	A2	20010620	EP 2000-126980	19921013 <--
EP 1108427	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 1108428	A2	20010620	EP 2000-126981	19921013 <--
EP 1108428	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 1484058	A2	20041208	EP 2004-15994	19921013 <--
EP 1484058	A3	20050427		
EP 1484058	B1	20081231		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 1484059	A2	20041208	EP 2004-15995	19921013 <--
EP 1484059	A3	20050420		
EP 1484059	B1	20080903		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
US 5635532	A	19970603	US 1993-135661	19931012 <--
IL 111251	A	20040620	IL 1994-111251	19941011 <--
CA 2173976	A1	19950420	CA 1994-2173976	19941012 <--
CA 2173976	C	20080219		
WO 9510271	A2	19950420	WO 1994-US11492	19941012 <--
WO 9510271	A3	19950622		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 702051	B2	19950504	AU 1994-79737	19941012 <--
AU 9479737	A	19950504		
EP 725635	A1	19960814	EP 1994-930694	19941012 <--
EP 725635	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09506079	T	19970617	JP 1995-511977	19941012 <--
JP 3628694	B2	20050316		
NZ 275673	A	20000929	NZ 1994-275673	19941012 <--
JP 2001253821	A	20010918	JP 2001-69516	19941012 <--
JP 2003119130	A	20030423	JP 2002-302292	19941012 <--
AT 285760	T	20050115	AT 1994-930694	19941012 <--
EP 1523982	A2	20050420	EP 2004-30912	19941012 <--
EP 1523982	A3	20050427		
EP 1523982	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT				

PT 725635	E	20050531	PT 1994-930694	19941012 <--
ES 2233931	T3	20050616	ES 1994-930694	19941012 <--
AT 388699	T	20080315	AT 2004-30912	19941012 <--
PT 1523982	E	20080625	PT 2004-30912	19941012 <--
ES 2303624	T3	20080816	ES 2004-30912	19941012 <--
US 5843994	A	19981201	US 1995-478264	19950607 <--
US 5883124	A	19990316	US 1995-484615	19950607 <--
US 5852056	A	19981222	US 1996-633833	19960410 <--
JP 2005139208	A	20050602	JP 2005-54743	20050228
JP 2005139209	A	20050602	JP 2005-54744	20050228
HK 1077204	A1	20090206	HK 2005-109253	20051020

PRIORITY APPLN. INFO.:

US 1991-779744	A2	19911021
US 1993-135661	A2	19931012
EP 1992-922550	A3	19921013
US 1994-207521	A	19940307
EP 1994-930694	A3	19941012
JP 1995-511977	A3	19941012
JP 2001-69516	A3	19941012
WO 1994-US11492	W	19941012
EP 2000-126980	A3	20001208
EP 2000-126981	A3	20001208

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 126:207539

AB Compns. and methods are disclosed for treating anemia, cancer, AIDS, or severe β -chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or (pharmaceutically acceptable) derivs. thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Also disclosed are intravesical methods of treatment of cancers with phenylacetate. Pharmacol.-acceptable salts alone or in combination, and methods of preventing AIDS and malignant conditions and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonoid (or other mevalonate pathway inhibitor) is disclosed for simultaneous, sep., or sequential use in treating a neoplastic condition in a subject. Also disclosed are methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:476838 CAPLUS

DOCUMENT NUMBER: 125:105162

ORIGINAL REFERENCE NO.: 125:19439a,19442a

TITLE: Compositions with adenosine derivatives and deaminase inhibitors for the treatment of parasitic and fungal infections and neoplasms

INVENTOR(S): Mccaffrey, Ronald P.; Wigzell, Hans L. R.; Sugar, Alan M.

PATENT ASSIGNEE(S): University Hospital, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9616664	A1	19960606	WO 1995-US15116	19951130 <--

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
 GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
 MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
 TM, TT
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
 IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
 NE, SN, TD, TG

US 5663155	A	19970902	US 1994-351068	19941130 <--
US 5679648	A	19971021	US 1994-351067	19941130 <--
CA 2206511	A1	19960606	CA 1995-2206511	19951130 <--
AU 9642411	A	19960619	AU 1996-42411	19951130 <--
EP 794787	A1	19970917	EP 1995-940768	19951130 <--
EP 794787	B1	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10511345	T	19981104	JP 1995-518891	19951130 <--
AT 232104	T	20030215	AT 1995-940768	19951130 <--

PRIORITY APPLN. INFO.:
 US 1994-351067 A 19941130
 US 1994-351068 A 19941130
 WO 1995-US15116 W 19951130

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 125:105162

AB Compns. are provided which comprise an adenosine derivative and a deaminase inhibitor for the prevention and treatment of fungal and fungal-like infections and parasitic infections by eukaryotic organisms. Parasitic infections which are treatable and preventable with these compns. include malaria, trypanosomiasis, leishmania, toxoplasmosis, sarcocystis, pneumocystis, schistosomiasis, blood flukes and elephantitis. Other infections which are treatable and preventable with these compns. are responsible for fungal diseases such as candidiasis, cryptococcosis, blastomycosis, aspergillosis, paracoccidioidomycosis and coccidioidomycosis, and the fungal-like diseases nocardiosis and actinomycosis. The invention also relates to methods for utilizing these compns. in treatment regiments. Treatments may be either in vivo or in vitro. In vivo treatments involve administration of compns. of the invention to mammals suspected or at risk of being infected with a parasitic or fungal organism. In vitro treatments involve incubation of cells, tissues, biol. products derived from living materials or foods with compns. of the invention to inhibit or prevent further infection. Also disclosed is the treatment or prevention of neoplastic disorders with the adenosine derivs. of the invention.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)

L6 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:444325 CAPLUS
 DOCUMENT NUMBER: 122:205194
 ORIGINAL REFERENCE NO.: 122:37213a,37216a
 TITLE: Anti-angiogenic compositions containing
 polymeric carriers for treatment of cancer and other
 diseases
 INVENTOR(S): Burt, Helen M.; Hunter, William L.; Machan, Lindsay
 S.; Arsenault, A. Larry
 PATENT ASSIGNEE(S): Angiogenesis Technologies, Inc., Can.
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9503036	A1	19950202	WO 1994-CA373	19940719 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2167268	A1	19950202	CA 1994-2167268	19940719 <--
CA 2167268	C	20040928		
CA 2468375	A1	19950202	CA 1994-2468375	19940719 <--
CA 2472373	A1	19950202	CA 1994-2472373	19940719 <--
CA 2472373	C	20091013		
CA 2472404	A1	19950202	CA 1994-2472404	19940719 <--
AU 9471192	A	19950220	AU 1994-71192	19940719 <--
AU 693797	B2	19980709		
EP 706376	A1	19960417	EP 1994-920360	19940719 <--
EP 706376	B1	19970625		
EP 706376	B2	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1130866	A	19960911	CN 1994-193379	19940719 <--
CN 1138505	C	20040218		
JP 09503488	T	19970408	JP 1995-504823	19940719 <--
JP 3423317	B2	20030707		
AT 154757	T	19970715	AT 1994-920360	19940719 <--
EP 797988	A2	19971001	EP 1996-119361	19940719 <--
EP 797988	A3	20001122		
EP 797988	B1	20090114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
ES 2106553	T3	19971101	ES 1994-920360	19940719 <--
EP 1155689	A2	20011121	EP 2001-117863	19940719 <--
EP 1155689	A3	20011128		
EP 1155689	B1	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1155690	A2	20011121	EP 2001-117872	19940719 <--
EP 1155690	A3	20011128		
EP 1155690	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1155691	A2	20011121	EP 2001-117876	19940719 <--
EP 1155691	A3	20020529		
EP 1155691	B1	20080917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1159974	A1	20011205	EP 2001-117873	19940719 <--
EP 1159974	B1	20070718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1159975	A2	20011205	EP 2001-117882	19940719 <--
EP 1159975	A3	20020327		
EP 1159975	B1	20080910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
RU 2180844	C2	20020327	RU 1996-105391	19940719 <--
JP 2002326930	A	20021115	JP 2002-66179	19940719 <--
NZ 511762	A	20030926	NZ 1994-511762	19940719 <--
CN 1502331	A	20040609	CN 2003-10119882	19940719 <--
AT 277649	T	20041015	AT 2001-117872	19940719 <--
NZ 523799	A	20050324	NZ 1994-523799	19940719 <--
CN 1704121	A	20051207	CN 2005-10082207	19940719 <--
NZ 533467	A	20060224	NZ 1994-533467	19940719 <--
EP 1632259	A2	20060308	EP 2005-20791	19940719 <--
EP 1632259	A3	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1652539	A1	20060503	EP 2005-20782	19940719 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1695697	A2	20060830	EP 2005-20783	19940719 <--
EP 1695697	A3	20071226		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1695698	A1	20060830	EP 2005-20792	19940719 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 339975	T	20061015	AT 2001-117863	19940719 <--
ES 2267638	T3	20070316	ES 2001-117863	19940719 <--
CN 100998565	A	20070718	CN 2006-10099887	19940719 <--
CN 100998869	A	20070718	CN 2006-10099889	19940719 <--
CN 101007173	A	20070801	CN 2006-10099890	19940719 <--
AT 367173	T	20070815	AT 2001-117873	19940719 <--
PT 1159974	E	20071031	PT 2001-117873	19940719 <--
ES 2290074	T3	20080216	ES 2001-117873	19940719 <--
CN 101185759	A	20080528	CN 2006-10099888	19940719 <--
EP 1946749	A1	20080723	EP 2008-6468	19940719 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 407712	T	20080915	AT 2001-117882	19940719 <--
AT 408429	T	20081015	AT 2001-117876	19940719 <--
AT 420628	T	20090115	AT 1996-119361	19940719 <--
PT 797988	E	20090519	PT 1996-119361	19940719 <--
ES 2321241	T3	20090603	ES 1996-119361	19940719 <--
KR 2009090403	A	20090825	KR 2009-715869	19940719 <--
KR 934111	B1	20091231	KR 2002-716338	19940719 <--
US 5716981	A	19980210	US 1995-478203	19950607 <--
US 5886026	A	19990323	US 1995-472413	19950607 <--
US 5994341	A	19991130	US 1995-478914	19950607 <--
US 20030203976	A1	20031030	US 1995-486867	19950607 <--
NO 9600226	A	19960318	NO 1996-226	19960118 <--
NO 324275	B1	20070917		
NZ 329193	A	20010831	NZ 1997-329193	19971117 <--
US 20020165265	A1	20021107	US 1997-984258	19971203 <--
AU 9869911	A	19980716	AU 1998-69911	19980604 <--
AU 728873	B2	20010118		
US 20020164377	A1	20021107	US 1999-294458	19990419 <--
US 6506411	B2	20030114		
AU 771815	B2	20040401	AU 2000-71746	20001122 <--
US 20030003094	A1	20030102	US 2001-925220	20010808 <--
US 6544544	B2	20030408		
US 20020119202	A1	20020829	US 2001-927882	20010809 <--
RU 2304433	C2	20070820	RU 2001-132111	20011128
US 20030004209	A1	20030102	US 2002-112921	20020328
US 6846841	B2	20050125		
HK 1042054	A1	20081114	HK 2002-103990	20020529
US 20040076672	A1	20040422	US 2003-389262	20030313
US 20040062810	A1	20040401	US 2003-390534	20030314
AU 2004200646	A1	20040311	AU 2004-200646	20040218
US 20050123605	A1	20050609	US 2004-959349	20041007
US 20050208137	A1	20050922	US 2004-959398	20041007
US 20050042295	A1	20050224	US 2004-962578	20041013
US 20060127445	A1	20060615	US 2005-151399	20050614
US 20060034932	A1	20060216	US 2005-206779	20050819
US 20060035830	A1	20060216	US 2005-206993	20050819
US 20060035831	A1	20060216	US 2005-207021	20050819
US 20060035832	A1	20060216	US 2005-207058	20050819
US 20060035833	A1	20060216	US 2005-207059	20050819
US 20060121117	A1	20060608	US 2006-332170	20060117
US 20060240113	A1	20061026	US 2006-435742	20060518
US 20070003629	A1	20070104	US 2006-435780	20060518
US 20070003630	A1	20070104	US 2006-435854	20060518
JP 2006328086	A	20061207	JP 2006-239650	20060904
JP 2007084572	A	20070405	JP 2006-331088	20061207
NO 2007003066	A	19960318	NO 2007-3066	20070615
US 20070298123	A1	20071227	US 2007-830080	20070730
US 20080020063	A1	20080124	US 2007-830186	20070730

US 20080166387	A1	20080710	US 2007-830240	20070730
US 20090074830	A1	20090319	US 2007-830208	20070730
AU 2007254682	A1	20080124	AU 2007-254682	20071224
KR 2008043375	A	20080516	KR 2008-707363	20080326
US 20090036517	A1	20090205	US 2008-98173	20080404
PRIORITY APPLN. INFO.:			US 1993-94536	A 19930719
			CA 1994-2167268	A3 19940719
			CN 2003-10119882	A3 19940719
			CN 2005-10082207	A3 19940719
			EP 1994-920360	A3 19940719
			EP 1996-119361	A3 19940719
			EP 2005-20792	A3 19940719
			JP 1995-504823	A3 19940719
			JP 2002-66179	A3 19940719
			KR 2002-716338	A3 19940719
			RU 1996-105391	A3 19940719
			WO 1994-CA373	W 19940719
			US 1995-417160	B3 19950403
			US 1995-478203	A1 19950607
			US 1995-478914	A1 19950607
			US 1995-480260	B1 19950607
			US 1995-486867	A1 19950607
			KR 1996-700266	A3 19960119
			US 1998-13765	B1 19980127
			AU 1998-69911	A3 19980604
			US 1999-294458	A1 19990419
			AU 2000-71746	A3 20001122
			US 2001-925220	A1 20010808
			US 2003-389262	B1 20030313
			US 2003-390534	A1 20030314
			AU 2004-200646	A3 20040218
			US 2004-959398	A1 20041007
			US 2004-962578	A1 20041013
			US 2006-435780	A1 20060518

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides compns. comprising an anti-angiogenic factor (e.g. anti-invasive factor, retinoic acid and its derivs., and taxol) and a polymeric carrier. Such compns. can be used to embolize a blood vessel nourishing a tumor, in a stent to enlarge a vessel lumen and thereby eliminate biliary, urethral, esophageal, and tracheal/bronchial obstruction, or to treat a tumor excision site by application to the resection margins,. Thus, growth of an explanted, angiogenic factor-secreting MDAY-D2 murine lymphoid tumor in the chick chorioallantoic membrane was suppressed by application of a polycaprolactone thermopaste containing 20% taxol.

OS.CITING REF COUNT: 155 THERE ARE 155 CAPLUS RECORDS THAT CITE THIS RECORD (261 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:503397 CAPLUS

DOCUMENT NUMBER: 113:103397

ORIGINAL REFERENCE NO.: 113:17371a,17374a

TITLE: Porphyrin and phthalocyanine antiviral compositions

INVENTOR(S): Schinazi, Raymond F.; Dixon, Dabney White; Marzilli, Luigi G.

PATENT ASSIGNEE(S): Georgia State University Foundation, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8911277	A2	19891130	WO 1989-US2256	19890523 <--
WO 8911277	A3	19891228		
W: AU, DK, FI, JP, KR, NO				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 5192788	A	19930309	US 1988-197764	19880523 <--
US 5109016	A	19920428	US 1989-355499	19890522 <--
AU 8938306	A	19891212	AU 1989-38306	19890523 <--
US 5281616	A	19940125	US 1992-873415	19920424 <--
PRIORITY APPLN. INFO.:			US 1988-197764	A 19880523
			US 1989-355499	19890522
			WO 1989-US2256	A 19890523

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Compns. for the inhibition of replication of human immunodeficiency virus (HIV) contain ≥ 1 porphyrins possessing antiviral activity. The virucides include porphyrins, phthalocyanines, chlorins, metallo derivs. thereof, and other porphyrin-like compds. The compns. are prepared as formulations with pharmaceutically acceptable carriers. Preferred are those carriers that will protect the active compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. No sp. example for the delivery system is given. The EC50 of e.g. di-Na protoporphyrin for inhibition of HIV replication in PBM cells was 0.48 μ M.

OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1990:151852 CAPLUS
DOCUMENT NUMBER: 112:151852
ORIGINAL REFERENCE NO.: 112:25475a,25478a
TITLE: Method and composition for inducing glycosaminoglycan accumulation in cancer therapy
INVENTOR(S): LaRocca, R. V.; Stein, C. A.; Myers, C. E.; Horne, M. K.; Constantopolous, G.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: U. S. Pat. Appl., 30 pp. Avail. NTIS Order No. PAT-APPL-7-301 377.
CODEN: XAXXAV
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 301377	A0	19890701	US 1989-301377	19890125 <--
WO 9008541	A1	19900809	WO 1990-US177	19900118 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9051592	A	19900824	AU 1990-51592	19900118 <--
PRIORITY APPLN. INFO.:			US 1989-301377	A 19890125
			WO 1990-US177	A 19900118

AB A method is described for inducing glycosaminoglycan accumulation by administering suramin for the treatment of metastatic adrenocortical cancer. It provides a method and composition for inhibiting lysosomal enzymes; it eliminates or reduces cachexia in patients suffering from certain neoplastic diseases. Intracerebral or i.v. administration of suramin causes an increase of glycosaminoglycan concentration in the liver and an increase in urinary glycosaminoglycan excretion.

```
=> s suramin(S)kit(S)instruction?
      3586 SURAMIN
        4 SURAMINS
      3587 SURAMIN
          (SURAMIN OR SURAMINS)
      47805 KIT
      44996 KITS
      78355 KIT
          (KIT OR KITS)
      27040 INSTRUCTION?
L7      0 SURAMIN(S)KIT(S)INSTRUCTION?
```

```
=> suramin(S)kit
SURAMIN(S)KIT IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s suramin(S)kit
      3586 SURAMIN
        4 SURAMINS
      3587 SURAMIN
          (SURAMIN OR SURAMINS)
      47805 KIT
      44996 KITS
      78355 KIT
          (KIT OR KITS)
```

```
L8      1 SURAMIN(S)KIT
```

```
=> d l8 ibib abs
```

```
L8  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:      2008:590746  CAPLUS
DOCUMENT NUMBER:       148:532718
TITLE:                 Test method using cells in artificially prepared
                        pattern in gelled matrix and test kit therefor
INVENTOR(S):           Hattori, Hideshi; Okochi, Norihiko; Kuroda, Masatoshi;
                        Hase, Masahiko
PATENT ASSIGNEE(S):    Dai Nippon Printing Co., Ltd., Japan
SOURCE:                U.S. Pat. Appl. Publ., 23pp.
                        CODEN: USXXCO
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20080113334	A1	20080515	US 2007-936836	20071108
JP 2008118900	A	20080529	JP 2006-305769	20061110
EP 1921450	A1	20080514	EP 2007-254412	20071108
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,				

AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.:

JP 2006-305769 A 20061110
JP 2006-305796 A 20061110

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides a method for performing a biol. test under conditions in which an artificially prepared cell pattern with initial position coordinates that can be determined is three-dimensionally cultured within a gelled matrix. The present invention relates to a biol. test method that comprises testing a biol. indicator with reference to at least one selected from the group consisting of cell proliferation, cell movement, and cell differentiation in a cell pattern substantially embedded in gel. The present invention also relates to a kit for the biol. test method. A glass substrate was coated with TSL 8350 reacted with triethylamine. The coated substrate was then reacted with sulfuric acid-treated tetraethylene glycol (TEG) to form a thin film of TEG on the substrate. UV photolithog. was used to prepare a pattern of cell adhesion regions on the substrate. Bovine aortic vascular endothelial cells were seeded and cultured on the cell adhesion regions of the substrate. The substrate was placed upside down on a collagen gel, cultured for 4 h, and carefully removed. Culture media was removed and fresh media containing VEGF, bFGF, and heparin was added. After 24 h of culture, new vessels growing from the existing pattern of cells were observed. In contrast, when suramin was added to the three-dimensional culture system, vascularization was completely inhibited.

=> d his

(FILE 'HOME' ENTERED AT 10:08:08 ON 19 APR 2010)

FILE 'REGISTRY' ENTERED AT 10:08:19 ON 19 APR 2010

L1 13 S SURAMIN
L2 1 S SURAMIN/CN

FILE 'CAPLUS' ENTERED AT 10:08:47 ON 19 APR 2010

L3 1812 S L2
L4 128 S L2 AND (COMPOSITION OR KIT)
L5 24 S L4 AND AD<20010924
L6 24 DUP REM L5 (0 DUPLICATES REMOVED)
L7 0 S SURAMIN(S)KIT(S)INSTRUCTION?
L8 1 S SURAMIN(S)KIT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.98	114.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-21.25	-21.25

STN INTERNATIONAL LOGOFF AT 10:15:05 ON 19 APR 2010